ArticleDiscover oncology2025
FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response.Translational oncology · 2026Article
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
- VASN Enhances IGF2BP3 Stability via USP10 Deubiquitination to Promote Triple-negative Breast Cancer Paclitaxel Resistance.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) lacks targeted therapies. FKBP10 contributes to oncogenesis and chemoresistance. We investigated FKBP10's prognostic value in TNBC.
methodsWe retrospectively analyzed 190 TNBC patients receiving neoadjuvant chemotherapy. Patients were stratified by FKBP10 expression (median AOD cutoff) and TP53 status. Cox regression identified prognostic factors for disease-free survival (DFS) and pathological complete response (pCR).
results34% achieved pCR. High FKBP10 expression correlated with worse DFS (HR = 0.50, 95%CI: 0.26-0.96, P = 0.03). Independent predictors of DFS included: N-stage (P = 0.021), age (P = 0.027), FKBP10/TP53 co-occurrence (P = 0.020), and pCR status (P = 0.005). FKBP10/TP53 co-occurrence predicted poor chemotherapy response (OR = 0.413, P = 0.016).
conclusionFKBP10 overexpression with TP53 mutation predicts poor prognosis and chemoresistance in TNBC. These biomarkers may guide treatment decisions, though prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.